Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.

Background: The FDA has recently proposed pre-marketing liver chemistry subject stopping criteria. The study was undertaken to determine the background rates of liver chemistry abnormalities in clinical trial populations without underlying liver disease.

Methods: Data from 28 Phase II-IV trials in diseases with normal risk of underlying liver abnormalities were included.